PTC Therapeutics Corp - PTCT EV/EBITDA Multiple

Corporate emblem and logo of PTC Therapeutics Corp (PTCT)

The EV/EBITDA enterprise value multiple chart for PTC Therapeutics, Inc. (PTCT) illustrates the dynamics of a company developing exclusive targeted therapies against genetic dystrophies based on RNA biology. Meanwhile, 12.29 represents the current metric value. Stability is supported by a diversified drug delivery network, although global clinical trials may slow down due to the international political isolation of certain countries.

PTCT (PTC Therapeutics Corp) EV/EBITDA Multiple history from 11/23/2025 to 11/14/2026

PTCT (ptcbio.com): analytical breakdowns and indicator data

- market price and analyst price targets:
Price Chart PTC Therapeutics Corp|PTCT - Broker Consensus Forecast
- issuer market value details:
Market Capitalization PTC Bio|PTCT - Total Enterprise Value
- issuer book value statistics:
Accounting Value per Share PTC Therapeutics|PTCT - Book Capitalization|Market Value to Book Value Ratio ptcbio.com|PTCT - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity PTC Therapeutics, Inc.|PTCT - Long-Term Liabilities to Capital|Short-Term Debt to Equity PTC Therapeutics|PTCT - Company Debts|Debt to Book Capitalization Ratio PTC Bio|PTCT - Long-Term Debt|Company Short-Term Debts PTC Therapeutics|Quick Liquidity Indicator ptcbio.com
- net income and valuation multiples indicators:
PTCT - Company Net Income|Expected Profit PTC Therapeutics, Inc.|PTCT - Market Cap to Net Income|Projected Price to Earnings PTC Therapeutics, Inc.|PTCT - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple PTC Bio|PTCT - Operating profit before deduction of amortization|Net earnings per share for the last 12 months PTC Therapeutics|PTCT - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months ptcbio.com|PTCT - Net earnings per one share growth for the current year|Earnings growth forecast for next year PTC Therapeutics, Inc.
- total revenue and sales volume data:
PTCT - Company Sales Revenue|Projected Sales Volume PTC Therapeutics Corp|PTCT - Price to Sales|Price-to-Projected Revenue Ratio PTC Bio
Summary company analytics:PTCT (PTC Therapeutics Corp)
Original product of PTC Therapeutics

This indicator compares enterprise value (EV) with operating profit before depreciation and amortization, allowing for an asset valuation that excludes debt load and tax distortions. The current EV/EBITDA ratio for PTC Therapeutics, Inc. (PTCT) at 12.29 reflects market expectations regarding clinical trial successes and regulatory approvals, which determine the value of PTC Therapeutics, Inc. (PTCT) regardless of general macroeconomic cycles.

Competitor analysis

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Jazz Pharma JAZZ|CYTK: Enterprise Value to Operating Income Before Depreciation|Scholar Rock - EV/EBITDA Multiple|Company Value to EBITDA centessa.com|DYN (Dyne Therapeutics) - Enterprise Value to EBITDA Ratio|Edgewise Therapeutics Inc (EWTX) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Rapport Pharma|ALMS: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Zevra Therapeutics (ZVRA)|CTNM - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Larimar Therapeutics, Inc. LRMR|Capricor Therapeutics Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TRDA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Channel Pharma|MNOV: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple serinatherapeutics.com SER|Enterprise Value to EBITDA Ratio BTAI|Company Value to EBITDA ProMIS PMN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Apimeds Pharmaceuticals (APUS)|AEON: Company Value to Operating Income Before Depreciation Ratio|NLS Pharmaceutics - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio BNOX (Bionomics Ltd.)|FSD Pharma Inc. - EV/EBITDA Multiple|Reata Pharmaceuticals Inc (RETA) - Enterprise Value to EBITDA Ratio